t2c 001

Drug Profile

t2c 001

Alternative Names: Autologous bone marrow-derived mononuclear cell fraction; t2c001; t2c001-AMI; t2c001-CHD; t2c001-DCM; t2c001-SW

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator t2cure
  • Class Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cardiomyopathies; Heart failure; Ischaemic heart disorders; Myocardial infarction; Thromboangiitis obliterans

Most Recent Events

  • 28 Jul 2015 No recent reports on development identified - Phase-I/II for Cardiomyopathy, Heart failure, Ischaemic heart disorders and Thromboangiitis obliterans in Germany (Intra-arterial)
  • 28 Jul 2015 No recent reports on development identified - Phase-II for Myocardial infarction in Germany (Intra-arterial)
  • 20 Sep 2010 t2c 001 receives Orphan Drug status for Thromboangiitis obliterans in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top